![[News] Japan Develops 10nm Nanoimprint Technology, with Potential to Tackle EUV Bottleneck – TrendForce](https://earth-news.info/wp-content/uploads/2025/12/329851-news-japan-develops-10nm-nanoimprint-technology-with-potential-to-tackle-euv-bottleneck-trendforce-360x180.jpg)
On Thursday, June 13, the Supreme Court affirmed the US Food and Drug Administration’s approval of the abortion pill mifepristone, thereby handing down its most important ruling on reproductive rights since its 2022 overturning of Roe v. Wade, the landmark decision that protected the national right to have an abortion.
In a 9-0 decision in FDA v. Alliance for Hippocratic Medicine, the justices found that the plaintiffs of a lawsuit that sought to pull the drug off the market lacked standing—that is, they did not have the right to bring the case to court.
“The plaintiffs do not prescribe or use mifepristone. And FDA is not requiring them to do or refrain from doing anything. Rather, the plaintiffs want FDA to make mifepristone more difficult for other doctors to prescribe and for pregnant women to obtain,” Justice Brett Kavanaugh wrote in the decision. “A plaintiff’s desire to make a drug less available for others does not establish standing to sue. Nor do the plaintiffs’ other standing theories suffice. Therefore, the plaintiffs lack standing to challenge FDA’s actions.”
The Supreme Court’s decision puts an end to a tangle of legal disputes in the lower courts that has caused widespread confusion over the legal status of mifepristone. It means the drug will remain legal to use in states that permit abortion and can continue to be distributed by mail.
Medical experts and health care providers applauded the court’s decision to uphold access to mifepristone.
“Mifepristone is safe, effective, and a crucial part of expanding abortion access in this post-Roe world,” says Kiki Freedman, CEO and cofounder of abortion telehealth provider HeyJane, adding that the company will continue to deliver evidence-based, compassionate medication abortion care.
Mifepristone was first approved by the FDA in 2000. It’s used in combination with a second pill, misoprostol, to induce an abortion within the first 10 weeks of pregnancy. It works by blocking a hormone called progesterone that’s needed for a pregnancy to continue, while misoprostol causes uterine contractions. In the United States, medication abortions are now more common than abortion procedures, accounting for more than 6 out of 10 abortions in 2023, according to the Guttmacher Institute.
Despite mifepristone’s established safety record, a group of antiabortion activists and doctors known as the Alliance for Hippocratic Medicine filed a lawsuit in November 2022 seeking to invalidate the FDA’s approval of the drug, claiming it’s too dangerous to be on the market. In the suit the alliance argued that mifepristone has led to increased emergency room visits, citing a 2021 study that was retracted earlier this year after an independent review found that its authors came to inaccurate conclusions.
In April 2023, Judge Matthew Kacsmaryk of the Northern District of Texas sided with the alliance and overturned the FDA’s approval of mifepristone, effectively instituting a nationwide ban on the drug’s use. The ruling caused shockwaves, as it demonstrated that the courts could revoke a drug’s approval and override the expertise of the FDA.
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Glamour – https://www.glamour.com/story/supreme-court-upholds-access-to-abortion-pill
